La Jolla Pharmaceutical Data On SSAO Candidates Presented At International Scientific Meeting

... La Jolla PharmaceuticalCompany (Nasdaq: LJPC) today announced that Matthew D. Linnik, Ph.D.,Executive Vice President of Research and Chief Scientific Officer,presented data concerning the Company's compounds that inhibit SSAO aspotential treatments for autoimmune and inflammatory diseases at the 12thAmine Oxidase and Trace Amines Workshop, in Rotterdam, The Netherlands. Dr. [click link for full article] ...